Key result
Female CHD patients report ~39% higher smoking rates than men despite similar lipid control.
Why the study?
Potential gender differences in cardiovascular risk factors and treatment patterns in secondary prevention of coronary heart disease were analyzed to reflect clinical practice.
Are there gender differences in cardiovascular risk factors and treatment patterns in patients eligible for secondary prevention of coronary heart disease?
Observational (n=9,135)
Yes
Are there gender differences in cardiovascular risk factors and treatment patterns in patients eligible for secondary prevention of coronary heart disease?
Absolute Event Rate: 11.7% vs 8.4%
p-value: p=<0.001
In a Swedish national cohort, secondary prevention of CHD showed equal levels of lipid control and access to medical drug treatment between men and women, though women reported higher smoking rates at 1 year.
Gender differences in secondary prevention may exist; leaves open whether sex-specific strategies improve outcomes.
OBJECTIVE: To analyse potential gender differences in cardiovascular risk factors and treatment patterns, reflecting clinical practice in secondary prevention. DESIGN: Observational national study during 3 years of patients eligible for secondary prevention of coronary heart disease (CHD). SETTING: Fifty-two healthcare districts in Sweden, involving primary health care and hospitals in collaboration, participating in a national quality assurance programme for the prevention of CHD. SUBJECTS: A national sample of male and female patients surviving acute myocardial infarction, or following CABG/PTCA interventions for CHD, controlled at 3-6 months (n = 9135) and 12 months (n = 4802) of follow-up. The proportion of female patients (25%) did not differ between visits. MAIN OUTCOME MEASURES: Self-reported data on lifestyle, drug treatment and cardiovascular risk factor levels after consultation in general practice or at hospital policlinics. RESULTS: No major gender differences were recorded in risk factor levels or in cardiovascular drug treatment patterns at 12 months of follow-up. Female patients participated in educational programmes to improve lifestyle to a higher degree than males (52.0 vs 45.1%), but after 1 year were more often (p < 0.001) self-reported smokers (11.7 vs 8.4%). Female patients showed higher levels of blood pressure, total cholesterol and HDL cholesterol, but not LDL cholesterol compared to male patients. CONCLUSIONS: In general, a gender-equal level of lipid control and access to medical drug treatment has been established for patients in secondary prevention from a national sample in Sweden, followed for 1 year after CHD manifestations and related interventions.
No takes yet. Share an insight, caveat, or question.
Nilsson et al. (2003) conducted an observational in Coronary heart disease (n=9,135). Female gender vs. Male gender was evaluated on Self-reported smoking at 1 year (p=<0.001). Female patients in secondary prevention for CHD had similar lipid control and drug treatment access as males at 1 year, but reported higher rates of smoking (11.7% vs 8.4%, p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: